Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease Collaboration to focus on the development of a formulation of Senju's SJP-0035 for use with Eyenovia's Optejet® dispensing technology, following consultation with FDA
Eyenovia insider buys $1m in company stock https://www.investing.com/news/company-news/eyenovia-insider-buys-1m-in-company-stock-93CH-3507696
Eyenovia Announces Share Offering and Warrants Sale The latest announcement is out from Eyenovia (EYEN). Eyenovia, Inc. has announced a registered direct offering to certain institutional and accredi…
Eyenovia Announces Pricing of $5M Registered Direct Offering NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it has entered into a securities purchase agreement with an institutional investor and its current largest stockholder, providing for the purchase and sale of 7,575,757 shares of common stock, and warrants to purchase up to 7,575,757 shares of common stock (the "Offering"). The combined offering price for each share of common stock and accompanying warrant is $0.66.
Eyenovia Announces Corporate Strategy Update Presentation Eyenovia (EYEN) just unveiled an announcement. Eyenovia, Inc. is set to unveil an updated corporate presentation to investors and analysts on June …
All You Need to Know About Eyenovia Rating Upgrade to Buy Eyenovia, Inc. (NASDAQ: EYEN ) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company''s changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time. As such, the Zacks rating upgrade for Eyenovia is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.
Eyenovia, Inc. (EYEN) Q1 2024 Earnings Call Transcript Eyenovia, Inc. (NASDAQ:EYEN ) Q1 2024 Results Conference Call May 14, 2024 4:30 PM ET Company Participants Eric Ribner - IR Michael Rowe - Chief Executive Officer John Gandolfo - Chief Financial Officer Bren Kern - Chief Operating Officer Conference Call Participants Matt Kaplan - Ladenburg Matthew Caufield - H.C. Wainwright Kemp Dolliver - Brookline Capital Markets Operator Good afternoon, ladies and gentlemen, and welcome to the Eyenovia First Quarter 2024 Earnings Conference Call.
Earnings call: Eyenovia reports Q1 2024 results, focuses on product pipeline https://www.investing.com/news/stock-market-news/earnings-call-eyenovia-reports-q1-2024-results-focuses-on-product-pipeline-93CH-3444491